In a recent study, researchers demonstrated that Z526, a novel dithiocarbamate-like compound, mitigates cancer-associated cachexia (CAC) both in vitro and in vivo.

Indeed, the next era of blockbuster cancer therapeutics could be focused on treating what ends up being the cause of death for up to 40% of cancer patients – cachexia. Historically, cachexia has ...

View Full Profile. Learn about our Editorial Policies. Cancer cachexia, or the wasting syndrome, is a catastrophic condition that causes dramatic and involuntary loss of muscle mass, fat and weight, ...

Vistagen has reported positive outcomes from the exploratory Phase IIA trial of an investigational pherine nasal spray, PH284, for the treatment of cancer cachexia. The 'previously unreported ...

In a recent study, researchers demonstrated that Z526, a novel dithiocarbamate-like compound, mitigates cancer-associated cachexia (CAC) both in vitro and in vivo.

Vistagen (VTGN) announced results from an exploratory Phase 2A study of PH284 in cancer cachexia. PH284 is an investigational pherine nasal spray differentiated from all current treatments for the ...

PH284 nasal spray increased hunger in cancer cachexia patients, showing a 71% improvement in subjective hunger scores compared to baseline. The phase 2A study demonstrated PH284's safety, with no ...

Two new composition of matter patents granted in the US and Europe Patents provide protection relating to lead compound S-pindolol benzoate ...

SOUTH SAN FRANCISCO, Calif., January 14, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry ...

“We are highly encouraged by the potential of PH284 to improve the quality of life for those challenged by the debilitating impacts of cancer cachexia,” stated Shawn Singh, President and Chief ...

Vistagen, a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, announced positive results from an exploratory phase 2A study of PH284 in cancer ...